In conclusion, loss of MK2 in the DC lineage results in the induction of a potent tumour-targeted cytotoxic T cell response upon local simultaneous delivery of a TLR agonist and tumour antigen. This evidence concerns the gene MAPKAPK2 and neoplasm.